The Filing Desk

ANI Pharmaceuticals vs Telix Pharmaceuticals

ANI Pharmaceuticals ANIP · Telix Pharmaceuticals TLX · Pharmaceuticals

ANI Pharmaceuticals reported revenue of $883 million in fiscal 2025, about the same as Telix Pharmaceuticals' $804 million in fiscal 2025. ANI Pharmaceuticals' revenue grew 43.8% in its latest year, and Telix Pharmaceuticals' grew 55.6%. ANI Pharmaceuticals had an operating margin of 12.6%, against 3.7% at Telix Pharmaceuticals. Free cash flow was $171 million at ANI Pharmaceuticals and −$43 million at Telix Pharmaceuticals.

Side by side

ANI PharmaceuticalsTelix Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$883M$804M
Revenue growth43.8%55.6%
Revenue growth a year, last 5 years33.5%—
Gross margin—53.0%
Operating margin12.6%3.7%
Net margin8.9%−0.9%
Free cash flow$171M−$43M
Free cash flow margin19.4%−5.3%
Return on capital15.9%5.0%
Net debt to EBITDA0.1x5.1x
Dividends and buybacks$13M$0M
Change in diluted share count9.9%−2.1%
Last close$69.13$8.71
P/E at the last close13.8×—
Insider trades, last 12 monthssold $13.6 millionbought $1.0 million, sold $0
Piotroski F-score6 of 82 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
ANI PharmaceuticalsTelix Pharmaceuticals
Operating margin
Percent of revenue
ANI PharmaceuticalsTelix Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ANI PharmaceuticalsTelix Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the ANI Pharmaceuticals and Telix Pharmaceuticals pages.